HARRIS & HARRIS GROUP ELECTS KELLY KIRKPATRICK TO BOARD OF DIRECTORS
Harris & Harris Group, Inc. announced today that its Board of Directors has expanded its size from eight to nine and has elected Kelly S. Kirkpatrick to fill the vacancy thus created.
Ms. Kirkpatrick is a consulting materials scientist based in San Francisco, California, focusing on areas of nanotechnology, genomics, advanced materials, biotechnology, transportation and environmental technologies. From 2000 to 2002, she served in the Office of the Executive Vice Provost of Columbia University as Director, Columbia Nanotechnology Initiative and Director for Research and Technology Initiatives. From 1998 to 2000, she served in the White House Office of Science and Technology Policy as a Senior Policy Analyst, where her responsibilities for the National Nanotechnology Initiative included managing representatives from six federal agencies on strategies research and development plan, implementation plan and a $495 million budget, organizing the Presidential review panel and co-writing the panel report. From 1997-1998, she was a Science Policy Coordinator for Sandia National Laboratories. From 1995-1996, she served in the Office of Senator Joseph J. Lieberman as Legislative Assistant, Congressional Science and Engineering Fellow. She received her Ph.D. in Materials Science and Engineering from Northwestern University in 1997.
The addition of Ms. Kirkpatrick to the Board of Directors reflects Harris & Harris Group's recent decision to focus its new business activities exclusively on small technology (small tech), including nanotechnology, microsystems technology and microelectromechanical (MEMS) technology. In 1994, Harris & Harris Group invested in its first small tech company, Nanophase Technologies Corporation, a spinoff from Argonne National Laboratory, which completed an initial public offering in 1997. Harris & Harris Group sold its interest in Nanophase in 2001 and invested part of the proceeds of the sale in August, 2001, in privately held Nantero, Inc., a company developing advanced seminconductors using nanotechnology and in February, 2002, in Nanopharma Corp., a research-based company founded to develop advanced drug delivery systems.
Harris & Harris Group is a Business Development Company with 8,864,231 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can also be found on its website at www.hhgp.com.
This press release may contain statements of a forward-looking nature relating to future events. Statements contained in this press release that are forward looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward looking statements to reflect new events or uncertainties.